Half-year report · HY
177A.TEDINET S100X2IH
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥258m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥380m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥272m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥417m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥274m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥367m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥795m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.0bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.3bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.4bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥202m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥916m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥518m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥518m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥467m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥220m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥39.53 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥157.57 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥55.7 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 65.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥283m |
| Cell Process Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥536m |
| Cell Process Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥536m |
| Cell Process Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥76m |
| Microbiological Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥686m |
| Microbiological Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥686m |
| Microbiological Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥36m |
| Tissue Culture Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Tissue Culture Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Tissue Culture Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥501m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥2.5bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥541m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥265m |
| Cell Process Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥630m |
| Cell Process Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥630m |
| Cell Process Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥191m |
| Microbiological Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥777m |
| Microbiological Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥777m |
| Microbiological Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥104m |
| Tissue Culture Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Tissue Culture Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| Tissue Culture Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥350m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥645m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 480
| Item | Context | Value | Unit |
|---|---|---|---|
| Land | Prior1YearInstant | 599172000 | JPY |
| Land | InterimInstant | 599172000 | JPY |
| Other net ppe | Prior1YearInstant | 1582638000 | JPY |
| Other net ppe | InterimInstant | 909456000 | JPY |
| Property plant and equipment | Prior1YearInstant | 3253652000 | JPY |
| Property plant and equipment | InterimInstant | 3462383000 | JPY |
| Intangible assets | Prior1YearInstant | 27262000 | JPY |
| Intangible assets | InterimInstant | 21620000 | JPY |
| Investments and other assets | Prior1YearInstant | 718768000 | JPY |
| Investments and other assets | InterimInstant | 721002000 | JPY |
| Noncurrent assets | Prior1YearInstant | 3999683000 | JPY |
| Noncurrent assets | InterimInstant | 4205005000 | JPY |
| Assets | Prior1YearInstant | 9066648000 | JPY |
| Assets | InterimInstant | 8843105000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 134081000 | JPY |
| Notes and accounts payable trade | InterimInstant | 139223000 | JPY |
| Electronically recorded obligations operating cl | Prior1YearInstant | 75344000 | JPY |
| Electronically recorded obligations operating cl | InterimInstant | 74949000 | JPY |
| Short term loans payable | Prior1YearInstant | 1500000000 | JPY |
| Short term loans payable | InterimInstant | 1500000000 | JPY |
| Current portion of long term loans payable | Prior1YearInstant | 150000000 | JPY |
| Current portion of long term loans payable | InterimInstant | 150000000 | JPY |
| Income taxes payable | Prior1YearInstant | 114136000 | JPY |
| Income taxes payable | InterimInstant | 75882000 | JPY |
| Provision for bonuses | Prior1YearInstant | 79840000 | JPY |
| Provision for bonuses | InterimInstant | 69864000 | JPY |
| Other cl | Prior1YearInstant | 433900000 | JPY |
| Other cl | InterimInstant | 325308000 | JPY |
| Current liabilities | Prior1YearInstant | 2487303000 | JPY |
| Current liabilities | InterimInstant | 2335227000 | JPY |
| Long term loans payable | Prior1YearInstant | 375000000 | JPY |
| Long term loans payable | InterimInstant | 300000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 46000000 | JPY |
| Net defined benefit liability | InterimInstant | 48585000 | JPY |
| Asset retirement obligations ncl | Prior1YearInstant | 66214000 | JPY |
| Asset retirement obligations ncl | InterimInstant | 66498000 | JPY |
| Other ncl | Prior1YearInstant | 310307000 | JPY |
| Other ncl | InterimInstant | 279614000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 797522000 | JPY |
| Noncurrent liabilities | InterimInstant | 694698000 | JPY |
| Liabilities | Prior1YearInstant | 3284826000 | JPY |
| Liabilities | InterimInstant | 3029926000 | JPY |
| Capital stock | Prior1YearInstant | 1253984000 | JPY |
| Capital stock | InterimInstant | 1253984000 | JPY |
| Capital surplus | Prior1YearInstant | 1153134000 | JPY |
| Capital surplus | InterimInstant | 1153134000 | JPY |
| Retained earnings | Prior1YearInstant | 3265071000 | JPY |
| Retained earnings | InterimInstant | 3344444000 | JPY |
| Shareholders equity | Prior1YearInstant | 5672189000 | JPY |
| Shareholders equity | InterimInstant | 5751563000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |